Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population

Elagolix, a gonadotrophin‐releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long‐term effects of BMD loss later in life cannot be directly assessed and has not been quantified. To address this gap in knowledge, this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilpatrick, Ryan D, Chiuve, Stephanie E, Leslie, William D, Wegrzyn, Lani R, Gao, Wei, Yang, Hongbo, Soliman, Ahmed M, Snabes, Michael C, Koenigsberg, Sarah, Zhong, Jia, Xiang, Cheryl, Watts, Nelson B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745882/
https://www.ncbi.nlm.nih.gov/pubmed/33354641
http://dx.doi.org/10.1002/jbm4.10401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745882/
https://www.ncbi.nlm.nih.gov/pubmed/33354641
http://dx.doi.org/10.1002/jbm4.10401

Ejemplares similares